melanocortin receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
== Human importance == In pisciculture and fishkeeping, the slime coat is important to the health of fish, particularly during transport which can cause damage to it. High ammonia levels in the water can also cause damage to the slime coat. The antimicrobial properties of fish slime have been studied as an alternative to antibiotic drugs to address antibiotic resistance.
The Harry Benjamin International Gender Dysphoria Association (HBIGDA), now known as the World Professional Association for Transgender Health (WPATH), was formed in 1979, with the first version of the Standards of Care published the same year. The Endocrine Society published guidelines for the hormonal care of transgender people in 2009, with a revised version in 2017. Hormone therapy for transgender women was initially done using high-dose estrogen therapy with oral estrogens such as conjugated estrogens, ethinylestradiol, and diethylstilbestrol and with parenteral estrogens such as estradiol benzoate, estradiol valerate, estradiol cypionate, and estradiol undecylate. Progestogens, such as hydroxyprogesterone caproate, medroxyprogesterone acetate, and other progestins, were also sometimes included. The antiandrogen and progestogen cyproterone acetate was first used in transgender women by 1977. Its use was standard at the Center of Expertise on Gender Dysphoria (CEGD; Kennis- en Zorgcentrum Genderdysforie, or KZcG) in Amsterdam, the Netherlands by 1985. Spironolactone, another antiandrogen, was first used in transgender women by 1986. These agents were described as allowing the use of much lower doses of estrogen than previously required, and this was considered advantageous due to risks of high doses of estrogens such as cardiovascular complications. Antiandrogens were well-established in hormone therapy for transgender women by the early 1990s. Estrogen doses in transgender women were reduced following the introduction of antiandrogens.
In February 2026, Singapore introduced a new bill legally requiring landowners along Singapore's coastline to implement or upgrade coastal defences in order to protect against rising sea levels. To reduce the country's dependence on fossil fuels, it has ramped up deployment of solar panels on rooftops and vertical surfaces of buildings, and other initiatives like building one of the world's largest floating solar farms at Tengeh Reservoir in Tuas.
=== Treatment === Gastrointestinal surgery can often be performed in the outpatient setting. In the United States in 2012, operations on the digestive system accounted for 3 of the 25 most common ambulatory surgery procedures and constituted 9.1 percent of all outpatient ambulatory surgeries.
Sources: en.wikipedia.org
Robert Lax (1938), minimalist poet Ed Rice (1940), Beat Generation writer Walter Farley (1941), author of The Black Stallion and its many sequels Thomas Gallagher (1941), winner of a 1960 Edgar Award and National Book Award for Fiction finalist Gerald Green (1942), writer of Holocaust and The Last Angry Man, co-creator of NBC's The Today Show Richard de Mille* (1944), writer and investigative journalist, son of director Cecil B. DeMille Jack Kerouac* (1944), Beat Generation author of On the Road Leonard Koppett (1944), sportswriter; recipient of the J. G. Taylor Spink Award and the Curt Gowdy Media Award Walter Wager (1944), mystery writer whose book 58 Minutes was adapted into Die Hard 2 Herbert Gold (1946), Beat Generation novelist Daniel Hoffman (1947), poet; 22nd United States Poet Laureate Hiag Akmakjian (1948), author Allen Ginsberg (1948), Beat Generation poet; author of Howl Frederick Karl (1948), literary biographer famous for his work on Joseph Conrad Stanley Loomis (1948), American expatriate writer Charles Simmons (1948), author, winner of the 1965 William Faulkner Foundation Award for notable first novel Louis Simpson (1948), poet; winner of the 1964 Pulitzer Prize for Poetry John Clellon Holmes (1949), Beat Generation novelist, Go John Hollander (1950), poet, MacArthur Fellow and winner of the Bollingen Prize Richard Howard (1951), translator and winner of the Pulitzer Prize for Poetry Anthony Robinson (1953), English professor and novelist Ralph Schoenstein (1953), humorist Dan Wakefield (1955), novelist, journalist, screenwriter John J.
=== Equipment loan program === Upon the conclusion of the SHIELD Illinois testing program, laboratory equipment and other hard assets were offered to public entities throughout the State of Illinois at no cost with the understanding that, should another pandemic occur, the equipment would be used however necessary to continue the mission of SHIELD Illinois to keep Illinois open.
Propanephosphonic acid anhydride (PPAA, T3P, Allessan CAP) is the trimeric anhydride of n-propylphosphonic acid. It is a useful reagent for peptide synthesis reactions, where it activates the carboxylic acid partner for subsequent reaction with a primary or secondary amine. It is commercially available as 50% solution in DMF or ethyl acetate as a slightly yellow mixture. Examples of Propanephosphonic acid anhydride being used in the industrial syntheses of pharmaceuticals include the Pfizer synthesis of dacomitinib, the Neurosearch synthesis of SNDRIs such as PC44156003, the last step of the synthesis of selinexor, and the synthesis of darolutamide.
== History of nanofiber production == Nanofibers were first produced via electrospinning more than four centuries ago. Beginning with the development of the electrospinning method, English physicist William Gilbert (1544-1603) first documented the electrostatic attraction between liquids by preparing an experiment in which he observed a spherical water drop on a dry surface warp into a cone shape when it was held below an electrically charged amber. This deformation later came to be known as the Taylor cone. In 1882, English physicist Lord Rayleigh (1842-1919) analyzed the unstable states of liquid droplets that were electrically charged, and noted that the liquid was ejected in tiny jets when equilibrium was established between the surface tension and electrostatic force. In 1887, British physicist Charles Vernon Boys (1855-1944) published a manuscript about nanofiber development and production. In 1900, American inventor John Francis Cooley (1861-1903) filed the first modern electrospinning patent. Anton Formhals was the first person to attempt nanofiber production between 1934 and 1944 and publish the first patent describing the experimental production of nanofibers. In 1966, Harold Simons published a patent for a device that could produce thin and light nanofiber fabrics with diverse motifs. Only at the end of the 20th century have the words electrospinning and nanofiber become common language among scientists and researchers. Electrospinning continues to be developed today.
== Abstracting and indexing == Matrix Biology is abstracted and indexed in BIOBASE, Biochemistry and Biophysics Citation Index, Biological & Agricultural Index, Biological Abstracts, BIOSIS Previews, Chemical Abstracts Service, Current Advances in Ecological and Environmental Sciences, Current Awareness in Biological Sciences, Current Contents, EMBASE, EMBiology, Genetics Abstracts, MEDLINE, Science Citation Index, and Scopus. According to the Journal Citation Reports, the journal has a 2024 impact factor of 4.6.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.